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Abstract
Neuroendocrine tumours (NETs) arising from dispersed endocrine system may originate from almost every location, although they are
most commonly found in the gastrointestinal tract and respiratory system. NETs are considered as particularly rare if they constitute less
than 1% of all neuroendocrine tumours.
The aim of the paper is to present ten rare NETs from the database of the Endocrinology Department of the Jagiellonian University,
Medical College: 4 NETs of the ampulla of Vater, 2 of the gallbladder, and 1 of the ovary, sphenoid sinus, Meckel’s diverticulum, and
epiglottis. The clinical presentation of such tumours and their management are discussed. (Pol J Endocrinol 2010; 61 (3): 322–327)
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Streszczenie
Guzy neuroendokrynne (NET) wywodzące się z rozproszonego układu komórek endokrynnych mogą lokalizować się nieomal w każdym
narządzie i tkance ludzkiego ciała, najczęściej jednak powstają w obrębie układu pokarmowego i oddechowego. Guzy neuroendokrynne
uważane są za szczególnie rzadkie, jeżeli ich częstość występowania nie przekracza 1% wszystkich nowotworów neuroendokrynnych.
Celem pracy było przedstawienie rzadkich NET z rejestru Katedry i Kliniki Endokrynologii Uniwersytetu Jagiellońskiego Collegium Medicum:
4 NET wywodzących się z brodawki Vatera, 2 z pęcherzyka żółciowego, 1 z jajnika, zatoki klinowej, uchyłka Meckela i nagłośni; oraz sposo-
bu postępowania w takich przypadkach.
(Endokrynol Pol 2010; 61 (3): 322–327)
Słowa kluczowe: guzy neuroendokrynne, rzadka lokalizacja NET, diagnostyka, rakowiak
Neuroendocrine tumours (NETs) arise from neuroen-
docrine cells (NECs). NECs are defined as cells 1) with
the ability to produce neurotransmitters, neuromodu-
lators, or neuropeptide hormones, 2) containing dense
core secretory granules, 3) and lacking axons and syn-
apses [1]. Since NECs form some of the classic endo-
crine glands, tumours of parathyroids, adrenal medul-
la, and medullary thyroid cancer are sometimes also
classified as NETs. Most of NECs are, however, dis-
persed in the mucosa of gastric and respiratory tracts,
forming one of the largest endocrine “organs” of the
human body. NECs are found in all solid organs, skin,
and mucous membranes; as a result, NETs can origi-
nate from almost every location [2] .
The incidence of NETs is as high as 5.25 cases per
100000 population per year [3], and is probably under-
estimated. Unsurprisingly, the most common location
of NETs is the gastrointestinal tract (about 70% of cas-
es), followed by the respiratory tract (about 25%), other
locations being extremely rare. However, in some parts
of the digestive tract or airways, NETs are a very unusu-
al finding, either because of NECs density (gallbladder,
biliary tract, oesophagus, larynx) or uncommon presen-
tation of the organ (Meckel’s diverticulum) [4–5].
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The aim of the study is to present and discuss the
clinical cases of NETs originating from unusual locations.
Results
In the NETs database of the Department of Endocri-
nology of the Jagiellonian University, Medical College,
comprising 244 patients mostly from the south-eastern
part of Poland, 10 tumours of unusual origin have been
registered so far. They are: 4 NETs of Vater’s ampulla,
2 NETs of the gallbladder, 1 NET of Meckel’s diverticu-
lum, 1 ovarian NET, 1 epiglottic NET, and 1 NET aris-
ing from the sphenoid sinus. A short description of
a few chosen cases, confirmed histopathologically by
positive chromogranin A and synaptophysin immun-
ostaining, is given below.
Case 1 — epiglottic NET
A 54-year-old male, tobacco smoker, with hoarse voice,
dyspnoe, swallowing problems, and enlarged neck
lymph nodes, underwent a horizontal laryngeal dissec-
tion with bilateral neck dissection due to the suspicion
of laryngeal cancer. The histopathological evaluation
revealed a poorly differentiated intermediate cell neu-
roendocrine carcinoma with multiple mitotic figures of
3 cm in diameter with loco regional lymph node me-
tastases (WHO/ENETS group 3). Subsequent irradiation
of the postsurgical lodge and loco regional lymph nodes
was performed. The post-therapeutic scintigraphy with
[99mTc-EDDA/HYNIC] octreotate (SRS, somatostatin recep-
tor scintigraphy) confirmed multiple nodal and bone me-
tastases (Fig. 1A and B). One year later, the patient received
one cycle of palliative peptide receptor radionuclide ther-
apy (PRRT) with mixed 177Lu/90Y-DOTA-TATE. Due to
progression of the disease with evolving superior caval
vain syndrome, the further therapy was stopped and the
patient died 1.5 years after initial diagnosis.
Case 2 — Meckel’s diverticulum NET
A 16-year-old male underwent surgery due to acute
appendicitis. In the muscular and serous layers of the
apparently unchanged Meckel’s diverticulum, which
was also removed during the laparotomy, small lesions
of well differentiated neuroendocrine tumour were
found. The margins of resection were tumour-free and
no angioinvasion was found (WHO/ENETS group 1B).
Postsurgical abdominal and chest CT scans, bronchos-
copy, digestive tract endoscopies, as well as repeated
SRS revealed no abnormalities. Chromogranin A and
urinary 5-OH-indole-acetic acid levels were within the
normal range. The patient is being followed up in the
Outpatient Clinic of the Endocrinology Department and
2 years and 2 months after surgery is disease-free.
Cases 3–4 — gallbladder NETs
A 46-year-old male with a history of acute pancreatitis
was admitted to the Surgery Department because of
acute abdominal symptoms. Gallbladder hydrops was
suspected and the patient underwent surgery. On his-
topathological examination, a neuroendocrine carcino-
ma of 1 cm in diameter with focal infiltration of the ad-
ipose tissue was discovered (WHO/ENETS group 2). The
patient received 6 cycles of chemotherapy with 5-FU.
The SRS performed post therapy was negative. The
patient was lost for further follow up after 8 months of
observation.
A 47-year-old female with symptoms related to
cholelithiasis was referred for cholecystectomy. On his-
topathological examination, a neuroendocrine tumour
of the gallbladder neck with low mitotic index was dis-
covered (WHO/ENETS group 1B). She was followed
with serial abdominal CTs and SRS. Ten years after the
surgery she is disease-free.
Case 5 — sphenoid sinus NET
A 51-year-old male with chronic headaches was diag-
nosed with a 4 cm pituitary mass. No other tumour-
related signs and symptoms were present. On head MR
the intra and extrasellar pituitary tumour was found
involving the sphenoid sinus and ethmoidal sinuses.
Lab tests confirmed hypogonadotropic hypogonadism.
He was operated on twice by transsphenoidal approach.
During the first procedure, a sphenoid sinus tumour
was removed and diagnosed immunohistochemically
as a well differentiated neuroendocrine tumour with
low MIB index (WHO/ENETS group 1B). During sec-
ond surgery, a silent corticotropinoma of the pituitary
was sub-totally excised. Postsurgical SRS was negative,
and CgA levels were within normal limits. The post-
surgery pituitary function test results were normal. Af-
ter surgery, the patient was diagnosed with benign,
non-functioning left adrenal gland adenoma. The pa-
tient has been followed up for 1 year and 8 months.
Case 6 — ovary NET
A 68-year-old female with carcinoid syndrome symp-
toms (cachexia, stomach aches, diarrhoea, mild flush-
es) underwent the bilateral salpingoovariectomy be-
cause of the tumour. Histopathological examination
revealed a neuroendocrine carcinoma probably arising
from the ovary (WHO/ENETS group 2). SRS confirmed
the neoplasm dissemination. The patient developed
heart failure due to carcinoid heart valve disease. She
was treated with cold somatostatin analogues, followed
by one cycle of 90Y-DOTA-TATE therapy. She died be-
fore completing the PRRT because of heart failure
6 months after initial diagnosis.
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Cases 7–10 — ampulla of Vater NETs
A 48-year-old female presented with jaundice. On ERCP
examination tumour of Vater’s ampulla was found.
Surgical excision of the duodenum, pancreatic head, and
loco-regional lymph nodes was performed. Immuno-
histochemical evaluation of the tumour specimens con-
firmed 0.7 cm diameter, poorly differentiated neuroen-
docrine carcinoma with high proliferation index — Ki67
Figure 1. SRS results of a patient with epiglottic NET (case 1): A. Chest SPECT; B. Whole body. Nodal and bone metastases marked
with arrows
Rycina 1. Wyniki badania SRS (scyntygrafia receptorów somatostatynowych) u pacjenta z NET nagłośni (przypadek 1): A. SPECT
klatki piersiowej. B. Całe ciało. Strzałki wskazują przerzuty do węzłów chłonnych i kości
A
B
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— 60%; the lymph nodes were negative for metastases
(WHO/ENETS group 3). The patient is being followed
up with imaging (SRS, abdominal and chest CT) and
CgA. One year after surgery she is free from disease.
A 67-year-old male was admitted to the surgery de-
partment due to jaundice. On ultrasound examination,
liver metastases were found. Pancreatoduodenectomy
with pancreatogastrostomy followed by partial liver
resection were performed. On histopathology, 1.5 cm
poorly differentiated neuroendocrine carcinoma of the
ampulla of Vater with high Ki-67 (20%) index was found
(WHO/ENETS group 3). The tumour was positive for
chromogranin A and cytokeratin, and negative for so-
matostatin and other specific hormones. The somatosta-
tin receptors expression in tumour tissues was negligi-
ble. On SRS, only weakly increased radiopharmaceuti-
cal uptake was seen in the 6th liver segment, making PRRT
inapplicable. The patient received two cycles of chemo-
therapy with: cisplatin, farmorubicin, 5-fluorouracil and
leucovorin. The therapy was stopped because of disease
progression. Serial abdominal CT imaging revealed pro-
gressive liver and nodal metastases. The patient has been
observed for 3 years and 1 month from initial diagnosis.
A 62-year-old female was evaluated because of
weight loss (8 kilos during 3 months). She denied other
symptoms and was negative for hyperbilirubinaemia.
A duodenal tumour was found on imaging and the
patient was referred for pancreatoduodenectomy. His-
topathological examination revealed well differentiat-
ed neuroendocrine carcinoma of the ampulla of Vater
(Ki-67 — 2.4%), infiltrating the duodenal wall and duc-
tus choledochus (WHO/ENETS group 2). The postsur-
gical SRS and abdominal CT were negative. Chromog-
ranin A levels were within normal range. Two years after
surgery the patient is disease-free.
A 42-year-old female underwent upper gastric tract
endoscopy due to abdominal pain and jaundice. A 2 cm
well differentiated neuroendocrine carcinoma of the
ampulla of Vater positive for somatostatin was found
and surgically removed (Ki-67 — 6%; WHO/ENETS
group 2). The postsurgical course was complicated by
fungal sepsis and intra-abdominal abscess. No local re-
currence was noted on conventional imaging one year
after the procedure. SRS performed two years after sur-
gery revealed weak non-specific tracer uptake in the
epigastric area. Chromogranin A was negative. Last
abdominal CT revealed infiltration of the right peri-re-
nal area — the patient was referred for surgical treat-
ment 2.5 years after initial diagnostic procedures.
Discussion
Modlin et al. have defined NETs as rare if they constitute
less than 1% of all neuroendocrine tumours [5]. So far,
about 110 cases of Vater’s ampulla NETs, 150 cases of gall-
bladder NETs, 170 Meckel’s diverticulum NETs, 280 cases
of laryngeal NETs, 500 ovarian NETs, and only about
30 NETs of paranasal sinuses have been reported (the
patient presented as Case 5 being the third description of
a neuroendocrine tumour located in the sphenoid sinus,
and probably the first of such NETs coexisting with pitu-
itary adenoma) [5–11]. There are some known risk factors
of NETs such as: smoking for laryngeal NETs and irradia-
tion for sino-nasal tract NETs [12–14]. Twenty-five per cent
of ampulla of Vater NETs are associated with von Reck-
linghausen disease [15], although none of the four patients
in our group had been diagnosed with neurofibromas.
Given that even in cases of a typical carcinoid, diagno-
sis is usually delayed by 5–7 years due to non-characteris-
tic symptoms, oligosymptomatic course of the disease, or
an inadequate awareness among physicians [16], these
very rare neoplasms are a real challenge for clinicians.
The NETs are usually diagnosed because of 1) symp-
toms related to the overproduction of hormones by the
tumours, 2) complaints related to the presence of the
pathological mass, or 3) as an incidental finding during
imaging due to other diseases, in surgical specimens (i.e.
carcinoid tumours of the appendix) or even during au-
topsy [17]. The hormone secretion-related syndromes
seem to develop less frequently in patients with rare
NETs. The ampulla of Vater NETs usually are manifest-
ed by symptoms of biliary obstruction, particularly jaun-
dice and itching [18–21], but also as gastrointestinal
bleeding [22]. They may be asymptomatic and found
incidentally [23], even if the immunohistochemical
staining for hormones is positive [24]. Symptoms (i.e.
diarrhoea) related to the somatostatin oversecretion
were also observed [25]. Gallbladder NETs are often
found incidentally during cholecystectomy, usually
preceded by symptoms mimicking cholecystitis or
cholelithiasis, sometimes accompanied by jaundice [26–
–29], rarely they cause syndromes related to excessive
hormones secretion, i.e. hyperinsulinaemic hypoglycae-
mia [30]. Patients with laryngeal NETs usually complain
of dysphagia, throat pain, dyspnea, and hoarseness
[5, 31], there are only a few reports of carcinoid syn-
drome associated with laryngeal tumours [13]. Clini-
cal manifestations of sphenoid sinus neuroendocrine
tumours include headaches, epistaxis, and cranial
nerve palsies [32]. Most of the patients with ovary
NETs present local symptoms (pain, acute abdomen,
pressure with defecation); however, due to direct
venous drainage of the ovaries to the inferior caval
vein, up to 38.9% cases — depending on tumour his-
topathology — develop carcinoid syndrome, includ-
ing carcinoid heart disease [6, 9, 33]. Constipation,
seen in many patients with ovarian NETs, may be
related to peptide YY production [5].
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Although NETs of rare origin are frequently non-
functioning, expression of active peptides and amines
are to be found on immunohistochemical staining of
the tumour, for example serotonin and somatostatin in
the ampulla of Vater NETs [15]. NETs may coexist, al-
though infrequently, with other neoplasms; adenocar-
cinomas have been reported in patients with gallblad-
der andampulla of Vater NETs [34–35].
Because the diagnosis of rare NETs is usually made
retrospectively, after obtaining the results of histopatho-
logical evaluation of primary tumour or metastases, the
imaging is usually used for disease staging and further
therapy planning. Somatostatin receptor nuclear imag-
ing, using either SPECT or PET modalities, seems par-
ticularly effective in localizing the primary tumour and
its metastases [36–37].
Surgery remains the best method of treatment for
NETs, regardless their localization. For localized disease
it provides the only possibility for complete remission
[4–5]. However, metastases to the regional lymph nodes
or distant metastases may be present at the time of sur-
gery, i.e. they are found in about 10% of patients with
gall bladder NETs, in up to 30% with ovarian NETs, and
in up to 70% with laryngeal NETs [4, 13]. The effective-
ness of adjuvant therapy with chemotherapy or radio-
therapy in rare disseminated NETs has not been evalu-
ated. For such patients, therapy with somatostatin ana-
logues has been proposed [37–38], particularly for car-
cinoid heart disease [39]. A radionuclide therapy
(90Yttrium or 177Lutetium- labelled analogues, 131I-MIBG)
may also be considered as the palliative one [40].
The prognosis and long-term survival in rare NETs
are related to the histopathological typing, the staging
at the time of the diagnosis, and the type and complete-
ness of the intervention. For localized and well differ-
entiated tumours treated with complete surgical resec-
tion, 5-year survival approaches 90% for ovary NETs
and 83% for Meckel’s diverticulum NETs [4, 41]. For
atypical carcinoids, the survival drops significantly: for
example 50% of patients with atypical laryngeal carci-
noid and only 5% with small cell cancers are alive after
5 years [12].
Conclusions
The NETs of rare location are usually diagnosed because
of local symptoms or incidentally. They very rarely
cause syndromes related to hormone overexpression.
Surgical treatment, if applicable, provides the possibili-
ty for complete remission. The prognosis in rare NETs
is related less to the primary lesion location than the
tumour grading, local invasion, presence of metastas-
es, and time of presentation.
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